Zepbound side effects most often involve the digestive tract — nausea, diarrhea, constipation, vomiting, and abdominal pain are reported by roughly one in four users in clinical trials. Most are mild, show up during the first weeks or during dose escalation, and fade over time. Less common but serious risks include pancreatitis, gallbladder disease, and kidney injury from dehydration. Here is what the FDA label and published trial data actually show about this weight-management injection.
What Zepbound Is and How It Works
Zepbound is the brand name for tirzepatide, a once-weekly injectable medication approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes. The same molecule is sold as Mounjaro for type 2 diabetes.
Tirzepatide is a first-in-class dual agonist: it activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Activating these gut-hormone pathways slows stomach emptying, improves insulin response to meals, and reduces appetite signaling in the brain. Because gastric emptying slows, food sits longer in the stomach — which is central to both the weight-loss effect and the most common side effects.
Common Zepbound Side Effects (From the FDA Label)
The table below summarizes the most frequent adverse reactions reported in the phase 3 SURMOUNT-1 trial (2,539 participants), as listed in the FDA prescribing information.
| Side Effect | Zepbound (any dose) | Placebo | Typical Timing |
|---|---|---|---|
| Nausea | ~29% | ~10% | First 4-8 weeks; dose increases |
| Diarrhea | ~21% | ~7% | First weeks |
| Constipation | ~17% | ~6% | Ongoing; often dietary |
| Vomiting | ~13% | ~2% | Dose escalation |
| Abdominal pain | ~10% | ~5% | Variable |
| Injection site reactions | ~8% | ~1% | First few injections |
| Fatigue | ~7% | ~3% | First weeks |
| Hair loss | ~5% | ~1% | After several months of weight loss |
Most GI symptoms are mild to moderate and transient. In SURMOUNT-1, fewer than 7% of participants discontinued Zepbound due to side effects — roughly double the 3% discontinuation rate in the placebo group.
Serious but Rare Risks
The FDA label lists several warnings. These are uncommon but important enough that clinicians screen for them before prescribing.
- Thyroid C-cell tumors (boxed warning): Rodents given tirzepatide developed thyroid tumors. Whether this applies to humans is unknown, but Zepbound is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
- Acute pancreatitis: Reported in trials. Stop the drug and seek care for severe, persistent abdominal pain, especially radiating to the back.
- Gallbladder disease: Rapid weight loss increases risk of gallstones and cholecystitis.
- Acute kidney injury: Usually tied to severe vomiting and dehydration; stay hydrated and call your clinician if you can’t keep fluids down.
- Hypoglycemia: Uncommon alone but real when combined with insulin or sulfonylureas — doses of those drugs often need to be reduced.
- Diabetic retinopathy complications: Rapid glucose improvement can transiently worsen retinopathy in people with pre-existing disease.
- Serious allergic reactions: Rare; includes anaphylaxis and angioedema.
- Suicidal thoughts: Monitor for new or worsening depression; report changes promptly.
Dosing and Why Titration Matters
Zepbound is started at 2.5 mg weekly for four weeks — a starter dose intended only to build tolerance, not for weight loss. It is then stepped up every four weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a maximum of 15 mg. Slow titration gives the gut time to adjust and is the single biggest lever for limiting nausea and vomiting.
Who Should Be Cautious
Zepbound is not for everyone. People with a history of medullary thyroid cancer, MEN 2, severe gastrointestinal disease (including gastroparesis), or prior pancreatitis are typically not candidates. It is also not recommended during pregnancy. If you have prediabetes or are considering weight loss as part of treatment, talk with your clinician about whether tirzepatide fits your overall plan — lifestyle change remains first-line and prediabetes is often reversible without medication.
The Bottom Line
Zepbound side effects are predominantly gastrointestinal: nausea, diarrhea, constipation, and vomiting that are typically mild and improve with time and slow titration. Serious risks — pancreatitis, gallbladder problems, kidney injury, and the rodent-based thyroid warning — are rare but real. Screening for contraindications, gradual dose escalation, and clear communication with your prescriber are the best ways to manage side effects safely. Always consult a qualified clinician before starting, stopping, or adjusting Zepbound.
This article is educational and does not replace personalized medical advice. Talk to your doctor about whether Zepbound is appropriate for you.
